1. Home
  2. CMCL vs LCTX Comparison

CMCL vs LCTX Comparison

Compare CMCL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caledonia Mining Corporation Plc

CMCL

Caledonia Mining Corporation Plc

HOLD

Current Price

$17.01

Market Cap

373.1M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

301.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCL
LCTX
Founded
1992
1990
Country
Jersey
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
373.1M
301.7M
IPO Year
2003
1996

Fundamental Metrics

Financial Performance
Metric
CMCL
LCTX
Price
$17.01
$1.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$28.00
$6.25
AVG Volume (30 Days)
271.7K
2.1M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
$38.54
$109.40
Revenue Next Year
N/A
N/A
P/E Ratio
$10.88
N/A
Revenue Growth
N/A
53.24
52 Week Low
$15.85
$0.93
52 Week High
$38.75
$2.09

Technical Indicators

Market Signals
Indicator
CMCL
LCTX
Relative Strength Index (RSI) 33.33 37.67
Support Level N/A N/A
Resistance Level $20.45 $1.32
Average True Range (ATR) 0.87 0.06
MACD -0.14 -0.01
Stochastic Oscillator 25.98 6.82

Price Performance

Historical Comparison
CMCL
LCTX

About CMCL Caledonia Mining Corporation Plc

Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: